NEOG
Neogen Corporation7.04
+0.19+2.77%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.53BP/E (TTM)
-Basic EPS (TTM)
-4.80Dividend Yield
0%Recent Filings
8-K
Q2 revenue dips, core grows
Neogen reported Q2 FY2026 revenue of $224.7 million, down 2.8% YoY but with core growth of 2.9% amid divestitures and FX. Adjusted EBITDA hit $48.7 million at 21.7% margin, boosted by no repeat goodwill impairment. Hires bolster commercial team; Petrifilm transition on track. Raised FY2026 guidance to $845-855 million revenue, ~$175 million Adjusted EBITDA. Integration delays loom.
10-Q
Q2 FY2026 results
Neogen's Q2 revenues dipped 3% y/y to $224.7M (derived), yet gross margin held at 47.5% despite sample collection inefficiencies and tariffs; operating loss narrowed sharply to $5.4M from $457.5M after last year's $461.4M goodwill hit. YTD revenue fell 3% to $433.9M, but swung to $20.4M net income ($0.09 diluted EPS, anti-dilution excluded 3.1M shares) on $76.4M gain from April 2025 Cleaners & Disinfectants sale for $121.7M cash. Cash climbed to $145.3M, operating cash flow rose 36% y/y to $30.3M (FCF not disclosed in the 10-Q), while debt dropped to $800M with $201.5M revolver availability. Genomics assets ($76.8M) sit held for sale. Ongoing shareholder suits over 3M integration cloud the path.
8-K
Neogen names new CFO Riggsbee
Neogen Corporation appointed Bryan Riggsbee as Senior Vice President and Chief Financial Officer, effective November 3, 2025, to lead its global finance operations amid a push for disciplined growth. With over 25 years in diagnostics, including CFO roles at bioMérieux's $2 billion North American unit and Myriad Genetics, Riggsbee brings expertise in portfolio expansion and international markets. His package includes a $600,000 base salary, 80% target bonus, $2 million annual equity, and $2.25 million sign-on equity. This bolsters leadership continuity, with prior CFO David Naemura staying through year-end.
8-K
Annual meeting elects directors, rejects pay
Neogen held its 2025 Annual Meeting on October 23, with 195 million shares voting. Shareholders elected directors Thierry Bernard, Mikhael Nassif, Avi Pelossof, and Andrea Wainer, but rejected exec pay by non-binding vote (167M for, 17.7M against). Auditors BDO ratified. Pay snub signals governance pressure.
10-Q
Q1 FY2026 results
Neogen's Q1 FY2026 revenues dipped 3.6% y/y to $209.2M, pressured by the Cleaners & Disinfectants divestiture, yet core growth edged up 0.3% amid strength in pathogen detection and genomics services. Gross margin slipped to 45.4% from 48.4%, hit by production inefficiencies in sample collection and tariff costs, while operating loss widened to $16.1M from a $2.3M profit, driven by higher G&A from transformation initiatives. The $76.4M gain on the July 2025 divestiture flipped net results to $36.3M profit ($0.17 diluted EPS), confirmed against 217.3M shares with no anti-dilution flagged. Cash climbed to $138.9M, bolstered by $10.9M operating cash flow, while debt fell to $800M after $100M repayments using sale proceeds; revolver availability stands at $201.5M with covenants met. Free cash flow hit $ -13.1M (derived). Ongoing shareholder litigation over 3M integration poses risks.
IPO
Website
Employees
Sector
Industry
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
IDXX
IDEXX Laboratories, Inc.
693.18-6.95
ILMN
Illumina, Inc.
131.56-3.36
ISPC
iSpecimen Inc.
0.41-0.01
NEO
NeoGenomics, Inc.
11.67-0.25
QGEN
Qiagen N.V.
45.01-0.43
TMO
Thermo Fisher Scientific Inc
570.16-5.75
WAT
Waters Corporation
378.53-6.89
WGS
GeneDx Holdings Corp.
141.72-8.89